| Jumlah Saham Beredar | 59,881,775 shares |
| Saham Orang Dalam | 27,918,436 shares |
| Kepemilikan oleh Orang Dalam | 46.62 % |
| Orang Dalam Sejati | 47 |
Skor Sentimen Orang Dalam
Skor Sentimen Orang Dalam mengidentifikasi perusahaan yang dibeli oleh orang dalam korporat.
Ini adalah hasil dari model kuantitatif multifaktor yang canggih yang mengidentifikasi perusahaan dengan tingkat akumulasi internal tertinggi. Model penilaian ini menggunakan kombinasi dari jumlah bersih orang dalam yang membeli dalam 90 hari sebelumnya, total saham yang dibeli sebagai persentase dari jumlah saham yang beredar, dan total saham yang dimiliki oleh orang dalam. Angka tersebut berkisar dari 0 hingga 100, dengan angka yang lebih tinggi menunjukkan tingkat akumulasi yang lebih tinggi dibandingkan dengan perusahaan sejenis, dan 50 adalah rata-rata.
Frekuensi Pembaruan: Setiap Hari
Skor Sentimen Petugas
Skor Sentimen Pejabat menemukan perusahaan yang dibeli oleh Pejabat Korporat.
Menurut definisi, Pejabat Korporasi adalah Orang Dalam Korporasi, tetapi tidak seperti beberapa Orang Dalam lainnya (Pemegang Saham 10% dan Anggota Dewan), Pejabat bekerja untuk perusahaan setiap hari, dan mereka menggunakan uang mereka sendiri saat bertransaksi . (Pemegang Saham 10% dan Anggota Dewan seringkali adalah manajer dana yang mengelola uang orang lain.) Dengan demikian, transaksi orang dalam yang dilakukan oleh Pejabat jauh lebih signifikan dan harus ditangani dengan tepat.
Seperti Skor Sentimen Internal, Skor Sentimen Pejabat adalah hasil dari model kuantitatif multi-faktor yang canggih yang mengidentifikasi perusahaan dengan tingkat akumulasi pejabat tertinggi.
Frekuensi Pembaruan: Setiap Hari
Metrik Utama Orang Dalam
Kartu ini menunjukkan peringkat perusahaan berdasarkan berbagai metrik internal. Peringkat persentil menunjukkan bagaimana perusahaan ini dibandingkan dengan perusahaan lain di pasar AS. Peringkat yang lebih tinggi menunjukkan situasi yang lebih baik.
Sebagai contoh, secara umum diterima bahwa pembelian oleh orang dalam perusahaan adalah indikator positif, sehingga perusahaan dengan lebih banyak pembelian oleh orang dalam akan mendapat peringkat lebih tinggi daripada perusahaan dengan lebih sedikit pembelian oleh orang dalam (atau bahkan penjualan oleh orang dalam).
Jumlah Bersih Pembelian oleh Orang Dalam (Peringkat)
0 ( )
2405 out of 11305Jumlah Bersih Pembelian oleh Orang Dalam adalah total jumlah orang dalam yang membeli dikurangi total jumlah orang dalam yang menjual dalam 90 hari terakhir. Peringkat persentil ditunjukkan di sini (kisaran dari 0 hingga 100%).
Persentase Saham yang Dibeli oleh Orang Dalam (Peringkat)
0.000 %( )
2392 out of 11224Persentase Saham yang Dibeli oleh Orang Dalam adalah total jumlah saham yang dibeli oleh orang dalam dikurangi total jumlah saham yang dijual oleh orang dalam dalam 90 hari terakhir, dibagi dengan total jumlah saham yang beredar dan dikalikan dengan 100.
Grafik Perdagangan Orang Dalam
Grafik berikut menunjukkan Eledon Pharmaceuticals, Inc. transaksi orang dalam. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Secara umum, melakukan transaksi di perusahaan mereka berdasarkan informasi material yang belum dipublikasikan adalah ilegal bagi orang dalam. Ini tidak berarti bahwa mereka dilarang melakukan transaksi apa pun di perusahaan mereka sendiri. Namun, mereka wajib melaporkan semua transaksi kepada SEC melalui Formulir 4.
Daftar Orang Dalam dan Metrik Profitabilitas
Tabel ini menampilkan daftar orang dalam yang diketahui, dan dibuat secara otomatis dari pengajuan yang diungkapkan kepada SEC. Selain nama, jabatan terbaru, dan sebutan direktur, pejabat, atau pemilik 10%, kami memberikan kepemilikan terbaru yang diungkapkan. Selain itu, jika memungkinkan, kami memberikan kinerja perdagangan historis untuk orang dalam tersebut. Kinerja perdagangan historis adalah rata-rata tertimbang dari kinerja transaksi pembelian pasar terbuka aktual yang dilakukan oleh orang dalam tersebut. Untuk informasi lebih lanjut tentang bagaimana ini dihitung, tonton webinar YouTube ini.
See our leaderboard of most profitable insider traders.
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
|
Apple Tree Partners Ii Lp
Director, 10% Owner -
[D]
|
4,218,641 | 4,218,641 | |
|
Apple Tree Partners II - Annex, L.P.
Director, 10% Owner -
[D]
|
3,568,438 | 3,568,438 | |
|
Apple Tree Partners IV, L.P.
Director, 10% Owner -
[D]
|
250,000 | 250,000 | |
| Timothy J Barberich Director - [D] | 121,077 | 121,077 | |
| Biotechnology Value Fund Ii Lp - | 113,152 | 220,460 | |
| Biotechnology Value Fund L P - | 113,152 | 220,460 | |
|
Bvf Gp Holdings Llc
10% Owner -
|
113,152 | 220,460 | |
| Bvf I Gp Llc - | 113,152 | 220,460 | |
| Bvf Ii Gp Llc - | 113,152 | 220,460 | |
|
Bvf Inc/il
10% Owner -
|
113,152 | 220,460 | |
|
Bvf Partners L P/il
10% Owner -
|
220,460 | 220,460 | |
| BVF Partners OS Ltd. - | 113,152 | 220,460 | |
| Biotechnology Value Trading Fund OS LP - | 113,152 | 220,460 | |
| Buckley Stephen Jr. Director - [D] | 11,000 | 11,000 | |
| Erez Chimovits Director - [D] | 3,183,314 | 3,183,314 |
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
| Cheryl Cohen Director - [D] | 0 | 0 | |
| Flesher Gregory J. Chief Executive Officer, Director - [D] [O] | 156,918 | 156,918 | |
| Karen Jean Ferrante | 62,000 | ||
| David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] | 9,000 | 9,000 | |
|
Seth Loring Harrison
Director, 10% Owner -
[D]
|
7,912,079 | 7,912,079 | |
| Jan Hillson | 20,000 | ||
| Lee Kalowski Chief Financial Officer - [O] | 40,953 | 40,953 | |
| Keith Katkin Director - [D] | 24,238 | 24,238 | |
| Kessler David A. | 12,000 | ||
| Jon Kuwahara See Remarks - [O] | 5,974 | 5,974 | |
|
Mark N Lampert
10% Owner -
|
113,152 | 220,460 | |
|
Lifesci Index Partners Llc
10% Owner -
|
1,065,867 | 1,065,867 | |
| Gary A Lyons Director - [D] | 0 | 0 | |
| June Lee | 20,000 | ||
| Paul Sean Little CHIEF FINANCIAL OFFICER - [O] | 10,000 | 10,000 | |
|
Logos Global Management LP
10% Owner -
|
224,071 | 224,071 |
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
| McBride John S. Chief Operating Officer - [O] | 0 | 0 | |
| Jodie Pope Morrison President and CEO, Director - [D] [O] | 57,566 | 57,566 | |
|
Ag Novartis
10% Owner -
|
4,493,458 | 4,493,458 | |
|
Bioventures Ltd Novartis
10% Owner -
|
4,493,458 | 4,493,458 | |
| Christine Ocampo See Remarks - [O] | 21,590 | 21,590 | |
| Walter C Ogier | 20,000 | ||
|
OrbiMed Israel BioFund GP Limited Partnership
Director, 10% Owner -
[D]
|
73,650 | 73,650 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
73,650 | 73,650 | |
| Steven Perrin President, Director - [D] [O] | 1,000 | 1,000 | |
| Gerald E Quirk | 62,000 | ||
|
Muneer A Satter
10% Owner -
|
1,771,688 | 1,771,688 | |
| Smith Bryan E. | 120,000 | ||
| Turkel Catherine C. President - [O] | 88,662 | 88,662 | |
|
Martin D Williams
10% Owner -
|
337,700 | 337,700 | |
|
Paul Yook
10% Owner -
|
1,065,867 | 1,065,867 | |
| Yanchik Joseph A., III Director - [D] | 51,092 | 51,092 |
Report errors via our new Insider Auditing Tool
Rekam Jejak Pembelian Orang Dalam - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ELDN / Eledon Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoretis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Ang Adjusted Shares ay ang jumlah saham yang disesuaikan dengan pemisahan saham (stock split).
Rekam Jejak Penjualan Orang Dalam - Analisis Kerugian Jangka Pendek
Dalam bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan dalam pasar terbuka yang tidak direncanakan oleh orang dalam yang dilakukan di ELDN / Eledon Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoretis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Ang Adjusted Shares ay ang jumlah saham yang disesuaikan dengan pemisahan saham (stock split).
Riwayat Transaksi
Klik ikon tautan untuk melihat riwayat transaksi lengkap. Transaksi yang dilaporkan sebagai bagian dari rencana perdagangan otomatis 10b5-1 akan memiliki tanda X di kolom yang bertanda 10b-5.
| Berkas Tanggal |
Perdagangan Tanggal |
Formulir | Orang Dalam | Ticker | Judul Keamanan | Kode | Langsung | Latihan Harga |
Satuan Harga |
Unit Diubah |
Nilai Diubah (1 ribu) |
Sisa Pilihan |
Sisa Saham |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 75,431 | 220,460 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 821,121 | 2,633,679 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1,031,385 | 3,361,803 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 86,341 | 145,029 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 837,146 | 1,812,558 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1,055,445 | 2,330,418 | ||||||
| 2022-11-23 | 2022-11-23 | 4 | Perrin Steven | ELDN | Common Stock | D | 2.5969 | 1,000 | 3 | 1,000 | ||||
| 2022-02-02 | 2022-02-01 | 4 | Gros David-Alexandre C | ELDN | Stock Option (right to buy) | D | 3.97 | 108,000 | 108,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Smith Bryan E. | ELDN | Stock Option (right to buy) | D | 3.97 | 120,000 | 120,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Ogier Walter C | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Perrin Steven | ELDN | Stock Option (right to buy) | D | 3.97 | 155,000 | 155,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | McBride John S. | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | LYONS GARY A | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Lee June | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Hillson Jan | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Katkin Keith | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Little Paul Sean | ELDN | Stock Option (right to buy) | D | 3.97 | 155,000 | 155,000 | |||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 975,412 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 58,688 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 1,274,973 | ||||||||
| 2021-12-21 | 2021-12-20 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 4.4800 | 2,000 | 9 | 9,000 | ||||
| 2021-08-19 | 2021-08-17 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 6.2100 | 4,000 | 25 | 7,000 | ||||
| 2021-06-14 | 2021-06-11 | 4 | Little Paul Sean | ELDN | Common Stock | D | 8.8700 | 10,000 | 89 | 10,000 | ||||
| 2021-06-10 | 2021-06-09 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 8.0100 | 3,000 | 24 | 3,000 | ||||
| 2021-05-04 | 2021-05-03 | 4 | Smith Bryan E. | ELDN | Stock Option (Right to Buy) | D | 9.91 | 158,500 | 158,500 | |||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -1,757 | 6,758 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -9,169 | 39,693 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -11,776 | 52,145 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -35 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -203 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -273 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 97,615 | 113,152 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 1,944 | 15,537 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 509,410 | 598,624 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 11,278 | 89,214 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 654,215 | 771,780 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 15,166 | 117,565 | ||||||
| 2020-12-04 | 2020-12-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 21.6000 | -103,200 | -2,229 | 73,650 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25.5507 | 9,098 | 232 | 224,071 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26.1740 | 15,000 | 393 | 214,973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 27.0200 | -27 | -1 | 199,973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25.8790 | 12,942 | 335 | 200,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26.6442 | -12,942 | -345 | 187,058 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26.4824 | 15,000 | 397 | 200,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25.9730 | 4,000 | 104 | 185,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24.5299 | 31,000 | 760 | 181,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24.0325 | 5,000 | 120 | 150,000 | ||||
| 2020-11-06 | 3 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 145,000 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 13,595 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 77,936 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 102,400 | ||||||||
| 2020-09-15 | 2020-09-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 500.00 | 1,167 | 1,167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 500.00 | 1,167 | 1,167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 500.00 | 2,145 | 2,145 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 500.00 | 5,907 | 5,907 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Gros David-Alexandre C | NVUS | Stock Option (Right to Buy) | D | 500.00 | 18,278 | 18,278 | |||||
| 2020-03-20 | 2020-03-19 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0.26 | 50,000 | 50,000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0.26 | 100,000 | 100,000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0.26 | 200,000 | 200,000 | |||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | |||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | |||||
| 2019-09-30 | 2019-09-26 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0.67 | 100,000 | 100,000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0.67 | 75,000 | 75,000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0.67 | 60,000 | 60,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Chimovits Erez | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-05-22 | 2019-05-21 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1.9114 | -2,937 | -6 | 156,918 | ||||
| 2019-05-22 | 2019-05-20 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1.9616 | -11,701 | -23 | 159,855 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1.9114 | -1,058 | -2 | 5,974 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1.9616 | -4,218 | -8 | 7,032 | ||||
| 2019-05-22 | 2019-05-21 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1.9114 | -1,914 | -4 | 88,662 | ||||
| 2019-05-22 | 2019-05-20 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1.9616 | -7,623 | -15 | 90,576 | ||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez | NVUS | Common Stock | I | 3.1000 | 646,204 | 2,003 | 3,183,314 | ||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 3.1000 | 646,204 | 2,003 | 3,183,314 | ||||
| 2019-05-02 | 2019-04-30 | 4 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, par value $0.01 per share | I | 2.7000 | -200 | -1 | 1,065,867 | ||||
| 2019-03-18 | 2019-03-14 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 3.72 | 25,000 | 25,000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 3.72 | 90,000 | 90,000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 25,000 | 171,556 | ||||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 3.72 | 50,000 | 50,000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20,000 | 98,199 | ||||||
| 2018-09-13 | 2018-09-12 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 5.0190 | 16,632 | 83 | 78,199 | ||||
| 2018-09-13 | 2018-09-11 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 4.5560 | 17,048 | 78 | 61,567 | ||||
| 2018-09-07 | 2018-09-05 | 4 | TURKEL CATHERINE C. By Spouse's IRA | NVUS | Common Stock | I | 3.9660 | 805 | 3 | 805 | ||||
| 2018-06-14 | 2018-06-13 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4.83 | 24,000 | 24,000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20,000 | 44,519 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 4.83 | 56,500 | 56,500 | |||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 30,700 | 146,556 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 4.83 | 12,000 | 12,000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 11,250 | 11,250 | ||||||
| 2017-11-06 | 2017-11-06 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4.21 | 50,000 | 50,000 | |||||
| 2017-07-10 | 2017-07-10 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 5.61 | 35,000 | 35,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 5.85 | 36,000 | 36,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Morrison Jodie Pope | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-05-26 | 2017-05-24 | 4 | OCAMPO CHRISTINE | NVUS | Stock Option (Right to Buy) | D | 5.50 | 52,500 | 52,500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 5.50 | 52,500 | 52,500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 5.50 | 250,000 | 250,000 | |||||
| 2017-05-11 | 3 | LYONS GARY A | NVUS | No Securities Owned | D | 0 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113,794 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113,794 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26,816 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26,816 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24,238 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24,238 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23,160 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23,160 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5,074,220 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5,074,220 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 9.9900 | 58,959 | 589 | 115,856 | ||||
| 2017-05-11 | 2017-05-10 | 4 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 9.9900 | 10,010 | 100 | 21,590 | ||||
| 2017-05-11 | 2017-05-10 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 9.9900 | 11,111 | 111 | 24,519 | ||||
| 2017-05-11 | 2017-05-09 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 2,537,110 | 2,537,110 | ||||||
| 2016-06-16 | 2016-06-15 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-16 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-03-15 | 2016-03-15 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 5.7400 | 8,000 | 46 | 11,000 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.37 | -20,000 | 37,878 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0.63 | -8,015 | 0 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.3700 | 20,000 | 27 | 57,566 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0.6300 | 8,015 | 5 | 37,566 | ||||
| 2015-12-17 | 2015-12-15 | 4 | Ferrante Karen Jean | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 9.65 | 189,000 | 189,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-11-12 | 2015-11-11 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 11.2500 | 3,000 | 34 | 3,000 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -13,500 | 186,678 | |||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 14.0100 | -13,500 | -189 | 0 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 13,500 | 57 | 13,500 | ||||
| 2015-09-08 | 2015-09-08 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13.1300 | -4,668 | -61 | 40,953 | ||||
| 2015-09-04 | 2015-09-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 12.9600 | -2,158 | -28 | 45,621 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.37 | -3,000 | 57,878 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0.63 | -7,000 | 8,015 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -564 | 312,736 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.3700 | 3,000 | 4 | 29,551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0.6300 | 7,000 | 4 | 26,551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.7000 | -564 | -8 | 19,551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 564 | 1 | 20,115 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -12,000 | 313,300 | |||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.7000 | -12,000 | -164 | 19,551 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 12,000 | 19 | 31,551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0.63 | -7,426 | 15,015 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 2.31 | -2,574 | 0 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0.6300 | 7,426 | 5 | 19,551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 2.3100 | 2,574 | 6 | 12,125 | ||||
| 2015-07-17 | 2015-07-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2580 | -3,566 | -51 | 4,493,458 | ||||
| 2015-07-15 | 2015-07-14 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.4100 | -27,861 | -401 | 4,497,024 | ||||
| 2015-07-15 | 2015-07-13 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2020 | -20,611 | -293 | 4,524,885 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -8,000 | 325,300 | |||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.7000 | -8,000 | -110 | 9,551 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 8,000 | 13 | 17,551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -8,000 | 333,300 | |||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.8300 | -8,000 | -111 | 9,551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 8,000 | 13 | 17,551 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -300 | 200,178 | |||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 14.2000 | -300 | -4 | 0 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 300 | 1 | 300 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -6,700 | 200,478 | |||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 14.0000 | -6,700 | -94 | 0 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 6,700 | 28 | 6,700 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -2,000 | 207,178 | |||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 14.0200 | -2,000 | -28 | 0 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 2,000 | 8 | 2,000 | ||||
| 2015-06-19 | 2015-06-17 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-18 | 2015-06-16 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2700 | -1,120 | -16 | 4,545,496 | ||||
| 2015-06-16 | 2015-06-12 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2000 | -5,919 | -84 | 4,561,393 | ||||
| 2015-06-16 | 2014-06-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2000 | -14,777 | -210 | 4,546,616 | ||||
| 2015-06-12 | 2015-06-11 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2000 | -27,875 | -396 | 4,567,312 | ||||
| 2015-05-28 | 2015-05-26 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 10.81 | 214,605 | 214,605 | |||||
| 2015-04-20 | 2015-04-16 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13.0000 | -4,567 | -59 | 47,779 | ||||
| 2015-04-13 | 3 | Cohen Cheryl | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-04-13 | 2015-04-09 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 11.08 | 25,000 | 25,000 | |||||
| 2015-04-06 | 2015-04-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 11.4500 | -2,258 | -26 | 52,346 | ||||
| 2015-03-20 | 2015-03-19 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.5000 | -46,141 | -669 | 4,595,187 | ||||
| 2015-03-20 | 2015-03-18 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.5000 | -3,000 | -44 | 4,641,328 | ||||
| 2015-01-12 | 3 | Buckley Stephen Jr. | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-01-12 | 2015-01-08 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14.49 | 25,000 | 25,000 | |||||
| 2014-10-17 | 2014-10-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 13.25 | 134,134 | 134,134 | |||||
| 2014-10-17 | 2014-10-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 13.25 | 50,671 | 50,671 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series E Preferred Stock | I | -8,013,003 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-3 Preferred Stock | I | -3,931,085 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-2 Preferred Stock | I | -457,728 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-1 Preferred Stock | I | -4,577,315 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 15.0000 | 150,000 | 2,250 | 1,771,688 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 1,621,688 | 1,621,688 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series E Preferred Stock | I | -24,199,308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-3 Preferred Stock | I | -24,046,035 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-2 Preferred Stock | I | -1,539,643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-1 Preferred Stock | I | -8,711,335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series C Preferred Stock | I | -14,604,833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-2 Preferred Stock | I | -644,786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-1 Preferred Stock | I | -798,067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series A Preferred Stock | I | -4,500,000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 15.0000 | 362,500 | 5,438 | 7,912,079 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 7,549,570 | 7,549,579 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series E Preferred Stock | D | -24,199,308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series D-3 Preferred Stock | D | -10,675,613 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 15.0000 | 237,500 | 3,562 | 3,568,438 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 3,330,938 | 3,330,938 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | 165,251 | 165,251 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series E Preferred Stock | D | -15,064,469 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-3 Preferred Stock | D | -13,222,826 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-2 Preferred Stock | D | -1,539,643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-1 Preferred Stock | D | -15,396,431 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 15.0000 | 325,000 | 4,875 | 4,644,328 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 4,319,328 | 4,319,328 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series E Preferred Stock | D | -809,955 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series D-3 Preferred Stock | D | -457,731 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Common Stock | D | 121,077 | 121,077 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-3 Preferred Stock | D | -13,370,422 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-2 Preferred Stock | D | -1,539,643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-1 Preferred Stock | D | -8,711,335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series C Preferred Stock | D | -14,604,833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-2 Preferred Stock | D | -644,786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-1 Preferred Stock | D | -798,067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series A Preferred Stock | D | -4,500,000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 4,218,632 | 4,218,641 | ||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250,000 | ||||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250,000 | ||||||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 15.00 | 218,417 | 218,417 | |||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Common Stock | D | 54,604 | 54,604 | ||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19,102 | ||||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19,102 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51,092 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51,092 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337,700 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337,700 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425,397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212,712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425,397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212,712 |
P
Pembelian sekuritas non-derivatif atau derivatif di pasar terbuka atau secara pribadi.
S
Penjualan terbuka atau penjualan pribadi atas sekuritas non-derivatif atau derivatif.
A
Hibah, penghargaan, atau perolehan sekuritas lainnya dari perusahaan (seperti opsi)
C
Konversi turunan
D
Penjualan atau pengalihan sekuritas kembali ke perusahaan.
F
Pembayaran harga pelaksanaan atau kewajiban pajak menggunakan sebagian sekuritas yang diterima dari perusahaan.
G
Pemberian sekuritas oleh atau kepada orang dalam.
K
Swap ekuitas dan transaksi lindung nilai serupa
M
Pelaksanaan atau konversi sekuritas derivatif yang diterima dari perusahaan (seperti opsi)
V
Transaksi yang dilaporkan secara sukarela pada Formulir 4.
J
Lainnya (disertai dengan catatan kaki yang menjelaskan transaksi tersebut)
